Drug Trials Snapshots: DAWNZERA - DAWNZERA (donidalorsen)

https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-dawnzera DAWNZERA is a prekallikrein-directed antisense oligonucleotide indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older.